Zhang Ji-Hu, Wu Xiang, Sills Matthew A
Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA.
J Biomol Screen. 2005 Oct;10(7):695-704. doi: 10.1177/1087057105279149. Epub 2005 Aug 29.
Despite a large body of references on assay development, assay optimization, strategies, and methodologies for high-throughput screening (HTS), there have been few reports on investigations of the efficiency of primary screening in a systematic and quantitative manner for a typical HTS process. Recently, the authors investigated the primary hit comparison and the effect of measurement variability by screening a library of approximately 25,000 random compounds in multiple replicate tests in a nuclear receptor recruitment assay with 2 different assay detection technologies. In this report, we utilized these sets of multiple replicate screening data from a different perspective and conducted a systematic data analysis in order to gain some insights into the hit-finding efficiency of a typical primary screening process. Specifically, hit confirmation, false-positive (declaration) rates, and false-negative rates at different hit cutoff limits were explored and calculated from the 2 different assay formats. Results and analyses provided some quantitative estimation regarding the reliability and efficiency of the primary screening process. For the 2 assay formats tested in this report, the confirmation rate (activity repeated at or above a certain hit limit) was found to be 65% or above. It was also suggested that, at least in this case, applying some hit-selection strategies, it is possible to decrease the number of false-negative or false-positive hits without significantly increasing the efforts in primary screening.
尽管有大量关于检测方法开发、检测优化、高通量筛选(HTS)策略和方法的参考文献,但对于典型的HTS过程,很少有关于以系统和定量方式研究初筛效率的报告。最近,作者通过在具有两种不同检测技术的核受体募集检测中对约25000种随机化合物库进行多次重复测试,研究了初筛命中比较和测量变异性的影响。在本报告中,我们从不同角度利用这些多次重复筛选数据集,并进行了系统的数据分析,以便深入了解典型初筛过程的命中发现效率。具体而言,从两种不同的检测形式中探索并计算了不同命中截断限下的命中确认、假阳性(声明)率和假阴性率。结果和分析提供了关于初筛过程可靠性和效率的一些定量估计。对于本报告中测试的两种检测形式,发现确认率(活性在或高于某个命中限重复出现)为65%或更高。还表明,至少在这种情况下,应用一些命中选择策略,可以在不显著增加初筛工作量的情况下减少假阴性或假阳性命中的数量。